StemCell Therapy

Manila: This Philippine federal government is definitely depending on biotechnology-based options throughout handling critical environmental and meals basic safety difficulties struggling with america.

Environment Admin Ramon Paje, during a the latest event with suv Quezon City paying attention to the 7th Nationwide Biotechnology 7 days, said medical is key in order to approaching crucial the environmental problems facing this Philippines, for example connection between climatic change including droughts, food safety and mitigation of effects via rental destruction.

Biotechnology is generally defined as the field of biology that utilizes residing creatures in addition to bioprocesses within engineering, drugs and other applications.

Paje stated that given the difficulties challenged simply by places such as Australia which can be as a result of climatic change and man-made maladies such as contamination, there is an enormous likely regarding biotechnology throughout protecting as well as enhancing the company’s environment.

The utilization of biotechnology, specifically in food items creation as well as remedies, is debatable trouble in the Australia as well as in different establishing in addition to civilized world.

Paje known that while the advantages of the actual safe utilization of medical throughout other sectors, specifically in agriculture as well as drugs, are actually increasingly recognized by the us government, vehicles identified the various troubles experiencing biotechnology, specially the alleged affect of genetically-modified microorganisms or even GMOs on the some people’s health, pets as well as the atmosphere.

Source:
http://www.biotechblog.org/rss.xml

In the two previous posts I have outlined what I believe to be the active phase III and II/III cell therapy trials, as well as the cell therapy products to have 'recently' obtained formal regulatory market approval in some jurisdiction.


In the course of doing that work, I came across the following industry-sponsored phase III cell therapy trials which appear to be inactive and those which failed or were terminated.


INACTIVE INDUSTRY PHASE III    

•     Aastrom              BRCs
•     Aldagen              ALD-101
•     Arblast               AMT-301
•     Avax                  Mvax
•     HepaLife Tech      HepaMate
•     KeraCure             KeraPac
•     t2cure                BMCs
•     TVAX                 TV-Brain
•     TVAX                 TV-Kidney-1

   
RECENTLY FAILED /TERMINATED INDUSTRY PHASE III   

•     ABH (now Shire)        Dermgraft
•     Cellerix                    Cx401

I don't imagine this is an exhaustive list but as I have encouraged in previous posts, I welcome feedback as to errors, corrections, or omissions.   I'm using the 2009-11 time-frame here.  I'll update the post accordingly.

http://www.celltherapyblog.com hosted by http://www.celltherapygroup.com

Source:
http://feeds.feedburner.com/CellTherapyBlog

Following is a list of cell therapy products approved recently (2010-11):    

•  Dendreon                           Provenge                           US
•  FCB-Pharmicell                 Hearticellgram-AMI           Korea
•  Fibrocell Sciences              Laviv                                  US
•  Living Cell Technologies    DIABECELL                     Russia

 Honorable mention goes to TiGenix' ChondroCelect approved in late 2009 representing the first EMA approval of an ATMP:

• TiGenix                              ChondroCelect                   EU

http://www.celltherapyblog.com hosted by http://www.celltherapygroup.com

Source:
http://feeds.feedburner.com/CellTherapyBlog

Good news for all Foreign CEOs of Global Pharma’s who left India after learning that, in India drug sales are driven by Freebies, and no one would listen to their advice to mend sales practices and unethical marketing practices.

Indian Government issues a strong dose of medicine . The new norms to hold pharma MDs, CEOs responsible for offering freebies to doc.

Under new guidelines drug firms will be barred from offering freebies to doctors — free travel tickets, hotel stay, gifts and hospitality, and the like. If any drug firm is found violating these guidelines, the responsibility would lie squarely with the MD and CEO of the respective company.

Further, the drug firms concerned may be prohibited from using brand names of competitive products in their promotional activities trying to claim superiority for its products.

The new guidelines would also prohibit drug firms to get doctors to endorse their products both online and offline

Source:
http://microarray.wordpress.com/feed/

Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss

Watch the latest video at <a href="http://video.foxnews.com">video.foxnews.com</a>

Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss

If you want to serve on the Institute of Medicine panel examining the $3 billion California stem cell agency, you have a chance during the next few weeks.

The panel has lost a member because of a conflict of interest and is now engaged in the process of replacing him. The IOM will consider both expressions of interest and suggestions for candidates. Currently, the panel has no member from California, which leaves it minus an important perspective.

Christine Stencel, senior media relations officer for the IOM, told the California Stem Cell Report that the IOM expects to fill vacancy by its meeting Jan. 24 in California.

David Scadden of Harvard resigned from the IOM/CIRM panel earlier this month because of his ties to Fate Therapeutics of San Diego, which lists him as a scientific founder.

Persons interested in serving or nominating candidates can email Adrienne Stith at Astith@nas.edu.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

The end of the year is a traditional time for the media to come up with lists of both the dubious and meritorious events and personages of the year. This year's nominations from a California stem cell researcher include Geron, Roman Reed and the new chairman of the California stem cell agency.

Paul Knoepfler, a stem cell scientist at UC Davis and one of the few stem cell scientists who blogs regularly, today revealed his awards for 2011. They ranged from the political cartoon of the year to the stem cell scientific issue of the year.

Geron was named in the "misstep of the year." Knoepfler wrote,

"You guys really screwed up by dropping your stem cell program in this manner. I believe this bordered on the unethical. I commend the actual stem cell scientists at Geron, but the person(s) who as leaders pulled the trigger on killing the stem cell program did wrong."

Roman Reed was named "stem cell activist of the year." Reed is the man who came up with the CIRM motto several years ago, "Turning stem cells into cures." He has long been active on stem cell issues, along with his equally hard-working father, Don Reed.

Jonathan Thomas, the relatively new chairman of the stem cell agency, was named "stem cell leader of the year." Thomas was elected chairman of the agency in June, replacing Bob Klein, who stepped down. Knoepfler wrote that Thomas "has impressed the stem cell community and made some very positive changes at CIRM to make an awesome organization even better."

Knoepfler has much more,  including the stem cell biotech of the year –
Advanced Cell Technology of Santa Monica, Ca. – which Knoepfler said has two hESC trials on track and an "impressive scientific leadership." Not to be overlooked is the stem cell scientific issue of the year – "warts" or genetic changes -- at least possible ones involving iPS cells. Knoepfler points out that the subject has drawn a vast number of citations in journal articles.

We should not forget the stem cell blog of the year, which came in as a tie between Stem Cell Network of Canada and Stem Cell Assays by William Gunn of San Diego and Alexey Berseney of Philadelphia. Knoepfler also mentioned the CIRM Research Blog, overseen by Amy Adams, and the California Stem Cell Report. Knoepfler said the California Stem Cell Report "is read by a who’s who of the stem cell world, and is a source of important information about CIRM," although Knoepfler said he wished the blog was more balanced "in terms of positive and critical stories." However, Knoepfler did note that several more positive items have appeared recently, but this analyst warns of the perils of excessive exuberance.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

A blogger on the web site of Los Angeles television station KNBC today supported a new multibillion bond measure for the California stem cell agency but with an interesting qualification.

Joe Mathews, author and a senior fellow at the New America Foundation, said the new bonds should be backed by a tax on the people and companies involved in the business of health care. He wrote,

"New stem cell moneys can't come out of funds that would otherwise go to other programs."

Mathews said voters "probably" shouldn't approve another multibillion dollar bond measure for CIRM that is paid back through the state's general fund. He wrote, however,

"(T)hat doesn't necessarily mean there shouldn't be another stem cell bond. California's major universities have invested in stem cell research, with help from the agency.

"Major researchers have relocated to the state. And the unknown nature of stem cell research's promise, while frustrating efforts to justify the research dollar for dollar, argues for doing more to learn more.

"What the state budget picture does require is that any stem cell bond should have a clear funding mechanism -- a specific tax or new revenue source (some sort of levy on companies and people involved in the business of health care) -- that would be more than enough to pay back any bond."

Mathews is co-author of "California Crackup: How Reform Broke the Golden State and How We Can Fix It," which declares that the initiative process is one of major fault points in California government. The initiative was used to create the $3 billion stem cell agency in 2004, making it immune from normal state government accountability and locking in funding that cannot be touched by the legislature or government despite any other financial needs of the state.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

(HealthDay News) -- Radiologists have developed a way to gain better insight into signs of heart disease by using cardiac CT scans that detect narrowed arteries and low blood flow.

CT scans use X-rays to create cross-sectional images of the body's internal anatomy. The scans can detect blockages in coronary arteries, but it's hard to tell if they're actually preventing blood from flowing to the heart.

In a new study, published Sept. 15 in the Journal of the American College of Cardiology, researchers at Massachusetts General Hospital explained how to gain more detailed pictures of what is going on inside the body, potentially giving doctors more information about the best treatment.

The research, based on tests in 34 cardiac patients, "is among the first demonstrations of the use of cardiac CT to detect both coronary artery stenosis and resulting myocardial ischemia simultaneously in a single examination," Dr. Ricardo C. Cury, a cardiac imaging specialist at the hospital's Heart Center and the study's principal investigator, explained in a hospital news release. Read more...

Cardiofy Heart Care Supplement

Source:
http://feeds.feedburner.com/integratedmedicine

Following is a list of cell therapy products approved recently (2010-11):    

•  Dendreon                           Provenge                           US
•  FCB-Pharmicell                 Hearticellgram-AMI           Korea
•  Fibrocell Sciences              Laviv                                  US
•  Living Cell Technologies    DIABECELL                     Russia

 Honorable mention goes to TiGenix' ChondroCelect approved in late 2009 representing the first EMA approval of an ATMP:

• TiGenix                              ChondroCelect                   EU

http://www.celltherapyblog.com hosted by http://www.celltherapygroup.com

Source:
http://feeds.feedburner.com/CellTherapyBlog

In the two previous posts I have outlined what I believe to be the active phase III and II/III cell therapy trials, as well as the cell therapy products to have 'recently' obtained formal regulatory market approval in some jurisdiction.


In the course of doing that work, I came across the following industry-sponsored phase III cell therapy trials which appear to be inactive and those which failed or were terminated.


INACTIVE INDUSTRY PHASE III    

•     Aastrom              BRCs
•     Aldagen              ALD-101
•     Arblast               AMT-301
•     Avax                  Mvax
•     HepaLife Tech      HepaMate
•     KeraCure             KeraPac
•     t2cure                BMCs
•     TVAX                 TV-Brain
•     TVAX                 TV-Kidney-1

   
RECENTLY FAILED /TERMINATED INDUSTRY PHASE III   

•     ABH (now Shire)        Dermgraft
•     Cellerix                    Cx401

I don't imagine this is an exhaustive list but as I have encouraged in previous posts, I welcome feedback as to errors, corrections, or omissions.   I'm using the 2009-11 time-frame here.  I'll update the post accordingly.

http://www.celltherapyblog.com hosted by http://www.celltherapygroup.com

Source:
http://feeds.feedburner.com/CellTherapyBlog

Good news for all Foreign CEOs of Global Pharma’s who left India after learning that, in India drug sales are driven by Freebies, and no one would listen to their advice to mend sales practices and unethical marketing practices.

Indian Government issues a strong dose of medicine . The new norms to hold pharma MDs, CEOs responsible for offering freebies to doc.

Under new guidelines drug firms will be barred from offering freebies to doctors — free travel tickets, hotel stay, gifts and hospitality, and the like. If any drug firm is found violating these guidelines, the responsibility would lie squarely with the MD and CEO of the respective company.

Further, the drug firms concerned may be prohibited from using brand names of competitive products in their promotional activities trying to claim superiority for its products.

The new guidelines would also prohibit drug firms to get doctors to endorse their products both online and offline

Source:
http://microarray.wordpress.com/feed/

Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss

Watch the latest video at <a href="http://video.foxnews.com">video.foxnews.com</a>

Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss

The end of the year is a traditional time for the media to come up with lists of both the dubious and meritorious events and personages of the year. This year's nominations from a California stem cell researcher include Geron, Roman Reed and the new chairman of the California stem cell agency.

Paul Knoepfler, a stem cell scientist at UC Davis and one of the few stem cell scientists who blogs regularly, today revealed his awards for 2011. They ranged from the political cartoon of the year to the stem cell scientific issue of the year.

Geron was named in the "misstep of the year." Knoepfler wrote,

"You guys really screwed up by dropping your stem cell program in this manner. I believe this bordered on the unethical. I commend the actual stem cell scientists at Geron, but the person(s) who as leaders pulled the trigger on killing the stem cell program did wrong."

Roman Reed was named "stem cell activist of the year." Reed is the man who came up with the CIRM motto several years ago, "Turning stem cells into cures." He has long been active on stem cell issues, along with his equally hard-working father, Don Reed.

Jonathan Thomas, the relatively new chairman of the stem cell agency, was named "stem cell leader of the year." Thomas was elected chairman of the agency in June, replacing Bob Klein, who stepped down. Knoepfler wrote that Thomas "has impressed the stem cell community and made some very positive changes at CIRM to make an awesome organization even better."

Knoepfler has much more,  including the stem cell biotech of the year –
Advanced Cell Technology of Santa Monica, Ca. – which Knoepfler said has two hESC trials on track and an "impressive scientific leadership." Not to be overlooked is the stem cell scientific issue of the year – "warts" or genetic changes -- at least possible ones involving iPS cells. Knoepfler points out that the subject has drawn a vast number of citations in journal articles.

We should not forget the stem cell blog of the year, which came in as a tie between Stem Cell Network of Canada and Stem Cell Assays by William Gunn of San Diego and Alexey Berseney of Philadelphia. Knoepfler also mentioned the CIRM Research Blog, overseen by Amy Adams, and the California Stem Cell Report. Knoepfler said the California Stem Cell Report "is read by a who’s who of the stem cell world, and is a source of important information about CIRM," although Knoepfler said he wished the blog was more balanced "in terms of positive and critical stories." However, Knoepfler did note that several more positive items have appeared recently, but this analyst warns of the perils of excessive exuberance.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

If you want to serve on the Institute of Medicine panel examining the $3 billion California stem cell agency, you have a chance during the next few weeks.

The panel has lost a member because of a conflict of interest and is now engaged in the process of replacing him. The IOM will consider both expressions of interest and suggestions for candidates. Currently, the panel has no member from California, which leaves it minus an important perspective.

Christine Stencel, senior media relations officer for the IOM, told the California Stem Cell Report that the IOM expects to fill vacancy by its meeting Jan. 24 in California.

David Scadden of Harvard resigned from the IOM/CIRM panel earlier this month because of his ties to Fate Therapeutics of San Diego, which lists him as a scientific founder.

Persons interested in serving or nominating candidates can email Adrienne Stith at Astith@nas.edu.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

A blogger on the web site of Los Angeles television station KNBC today supported a new multibillion bond measure for the California stem cell agency but with an interesting qualification.

Joe Mathews, author and a senior fellow at the New America Foundation, said the new bonds should be backed by a tax on the people and companies involved in the business of health care. He wrote,

"New stem cell moneys can't come out of funds that would otherwise go to other programs."

Mathews said voters "probably" shouldn't approve another multibillion dollar bond measure for CIRM that is paid back through the state's general fund. He wrote, however,

"(T)hat doesn't necessarily mean there shouldn't be another stem cell bond. California's major universities have invested in stem cell research, with help from the agency.

"Major researchers have relocated to the state. And the unknown nature of stem cell research's promise, while frustrating efforts to justify the research dollar for dollar, argues for doing more to learn more.

"What the state budget picture does require is that any stem cell bond should have a clear funding mechanism -- a specific tax or new revenue source (some sort of levy on companies and people involved in the business of health care) -- that would be more than enough to pay back any bond."

Mathews is co-author of "California Crackup: How Reform Broke the Golden State and How We Can Fix It," which declares that the initiative process is one of major fault points in California government. The initiative was used to create the $3 billion stem cell agency in 2004, making it immune from normal state government accountability and locking in funding that cannot be touched by the legislature or government despite any other financial needs of the state.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

http://www.StemCellTreatment.org Thanks to adult stem cell research, stem cell therapy is going mainstream. Many celebrities and professional athletes are getting adult stem cell treatment and helping to open the doors for eventual full authorization here in the United States.

Link:
Adult Stem Cell Research - Video

Stem cells are the body's repair cells. They have the ability to divide and differentiate into many different types of cells based on where they are needed throughout the body. Stem cells can divide and turn into tissues such as skin, fat, muscle, bone, cartilage, and nerve to name a few.

See the article here:
Medivet's Stem Cell Therapy Featured on Animal Planets Dogs 101 - Video